NASDAQ:THAR

Tharimmune (THAR) Stock Price, News & Analysis

$0.36
-0.01 (-2.70%)
(As of 05/17/2024 ET)
Today's Range
$0.36
$0.38
50-Day Range
$0.36
$0.47
52-Week Range
$0.34
$12.48
Volume
82,694 shs
Average Volume
162,863 shs
Market Capitalization
$4.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
THAR stock logo

About Tharimmune Stock (NASDAQ:THAR)

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

THAR Stock Price History

THAR Stock News Headlines

Tharimmune, Inc. (THAR)
Tharimmune Inc THAR
Crude Oil Surges 2%; Tharimmune Shares Plummet
Why Is Tharimmune (THAR) Stock Down 70% Today?
Why Is Tharimmune (THAR) Stock Up 113% Today?
See More Headlines
Receive THAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tharimmune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
5/18/2024
Next Earnings (Estimated)
8/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:THAR
Previous Symbol
NASDAQ:THAR
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Net Income
$-9,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.60 per share

Miscellaneous

Free Float
11,511,000
Market Cap
$4.26 million
Optionable
Not Optionable
Beta
1.61
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Randy D. Milby MBA (Age 70)
    President, Chairman & CEO
    Comp: $593.75k
  • Mr. Sireesh Appajosyula Pharm.D. (Age 48)
    COO & Director
    Comp: $584.8k
  • Mr. Thomas P. Hess CPA (Age 60)
    MBA, Chief Financial Officer

THAR Stock Analysis - Frequently Asked Questions

How have THAR shares performed in 2024?

Tharimmune's stock was trading at $0.5090 at the beginning of 2024. Since then, THAR shares have decreased by 29.1% and is now trading at $0.3610.
View the best growth stocks for 2024 here
.

When is Tharimmune's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024.
View our THAR earnings forecast
.

How were Tharimmune's earnings last quarter?

Tharimmune, Inc. (NASDAQ:THAR) announced its earnings results on Thursday, May, 9th. The company reported ($0.19) EPS for the quarter.

When did Tharimmune's stock split?

Tharimmune shares reverse split on the morning of Tuesday, November 21st 2023. The 1-25 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Tharimmune?

Shares of THAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:THAR) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners